Filter Results
Clinical Studies
Results filtered:Study status:
Closed for Enrollment
Closed for Enrollment
-
An Open Label Pilot Trial of Erlotinib (Tarceva) in Primary Sclerosing Cholangitis with Trisomy 7
Rochester, Minn.
Primary sclerosing cholangitis is a chronic inflammation of the bile ducts of unknown cause and eventually results in cirrhosis of the liver. These patients are at increased risk for the development of cancer rising from bile duct tissue. Chromosomal abnormalities of the bile duct tissue, particularly trisomy 7 (i.e. three copies of chromosome 7) can be detected in biopsy samples. Erlotinib (Tarceva) is a human EGFR type 1 tyrosine kinase inhibitor and offers greater survival benefit to EGFR positive patients. This study will assist in determining the safety and tolerability of Tarceva in patients who have primary sclerosing cholangitis.
.